Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 7/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.35 |
| ▸ | GOT1 | P17174 | 1/20 | 0.35 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.35 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899381 | 1.00 | GSK3B (0.44) | GSK3BIDH1ANPEPADRA2AADRA2B | |
| SCHEMBL4894657 | 1.00 | GSK3B (0.44) | GSK3BIDH1ANPEPADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL31278251 | 0.98 | GSK3B (0.43) | GSK3BIDH1ANPEPADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL4069595 | 0.98 | GSK3B (0.43) | GSK3BIDH1ANPEPADRA2AADRA2B | |
| SCHEMBL29415789 | 0.84 | ANPEP (0.42) | GSK3BIDH1ANPEPCRBN | |
| SCHEMBL22509084 | 0.84 | ANPEP (0.42) | GSK3BIDH1ANPEPCRBN | |
| SCHEMBL8621250 | 0.84 | ANPEP (0.42) | GSK3BIDH1ANPEPCRBN | |
| SCHEMBL8274744 | 0.80 | GSK3B (0.51) | GSK3BIDH1ADRA2AADRA2BADRA2C | |
| SCHEMBL24408273 | 0.75 | SMYD3 (0.32) | — | |
| Hydrochloric Acid SCHEMBL30546650 | 0.74 | GSK3B (0.37) | GSK3BIDH1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005020987-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSES GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | claimed |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2021249417-A1 | HETEROCYCLIC COMPOUND AND DERIVATIVE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2021-12-16 | — | — | WO | disclosed |
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1819332-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LTD (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| EP-1758863-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | AstraZeneca AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005020987-A1 | HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSES GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | GSK3B 489/4885IDH1 1026/4885ANPEP 1987/4885 |
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PC, GOT2, PDK1 | GSK3B 3463/4885IDH1 79/4885ANPEP 1202/4885 |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | GSK3B 1748/4885IDH1 582/4885ANPEP 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.